Avidity Biosciences Inc

NASDAQ:RNA   3:59:44 PM EDT
29.95
-0.78 (-2.54%)
Earnings Announcements

Avidity Biosciences Reports Third Quarter 2020 Financial Results And Recent Highlights

Published: 11/10/2020 21:28 GMT
(RNA) - Avidity Biosciences Reports Third Quarter 2020 Financial Results and Recent Highlights.
Avidity Biosciences - Collaboration Revenue, Including Reimbursable Expenses, Was $1.7 Million for Q3 2020 Versus $0.7 Million for Q3 of 2019.
Avidity Biosciences Inc Qtrly Net Loss per Share, Basic and Diluted $0.31.
Revenue is expected to be $0.84 Million
Adjusted EPS is expected to be -$0.34

Next Quarter Revenue Guidance is expected to be $0.43 Million
Next Quarter EPS Guidance is expected to be -$0.38

More details on our Analysts Page.